{"analyses":[{"ciLowerLimit":"0.19","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.85","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY","pValue":"0.016","paramType":"Hazard Ratio (HR)","paramValue":"0.41","statisticalMethod":"Stratified log rank test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"25.1","upperLimit":"65.1","value":"46.3"},{"groupId":"OG001","lowerLimit":"3.6","upperLimit":"32.1","value":"14.3"}]}],"title":"PFS rate at 6 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.5","upperLimit":"42.0","value":"23.1"},{"groupId":"OG001","lowerLimit":"3.6","upperLimit":"32.1","value":"14.3"}]}],"title":"PFS rate at 9 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.6","upperLimit":"24.9","value":"6.9"},{"groupId":"OG001","lowerLimit":"3.6","upperLimit":"32.1","value":"14.3"}]}],"title":"PFS rate at 12 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"63"}],"units":"Participants"}],"description":"Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause\n\nKaplan-Meier estimate was used.","dispersionType":"95% Confidence Interval","groups":[{"description":"Capivasertib: 400 mg twice daily (2 tablets of 200 mg taken orally twice daily; total daily dose 800 mg) given on an intermittent weekly dosing schedule (4 days on/3 days off).\n\nFulvestrant: 500 mg (2 intramuscular injections of 250 mg/5 mL solution) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter.","id":"OG000","title":"Capivasertib + Fulvestrant (Global + China Cohort)"},{"description":"Placebo: Placebo tablets matching capivasertib. 400 mg twice daily (2 tablets of 200 mg taken orally twice daily; total daily dose 800 mg) given on an intermittent weekly dosing schedule (4 days on/3 days off).\n\nFulvestrant: 500 mg (2 intramuscular injections of 250 mg/5 mL solution) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter.","id":"OG001","title":"Placebo + Fulvestrant (Global + China Cohort)"}],"paramType":"NUMBER","populationDescription":"Altered subgroup full analysis set in the China cohort","reportingStatus":"POSTED","timeFrame":"Assessed every 8 weeks for the first 2 years following objective disease progression or treatment discontinuation and then every 12 weeks.","title":"Progression Free Survival: Altered Population (Percentage) in the China Cohort","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}